AGMB insider transactions
AgomAb Therapeutics NV (AGMB) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.
AGMB insiders
Everyone who has filed a Form 3, 4, 5 or 144 at AgomAb Therapeutics NV, latest first. Follow anyone to get their next filing.
- David R EpsteinDirector, since March 2026+$104K
- Marino GarciaDirector, since September 2026
- Naimish PatelDirector, since September 2026
- Ellen LefeverGeneral Counsel, since March 2026
- Andrea Saez BorderiasChief Development Officer, since March 2026
- Paul Henryk van der HorstChief Business Officer, since March 2026
- Verduyn-van Weegen Felice IsabelDirector, since March 2026
- Kemula Pierre Thadee VictorChief Financial Officer, since March 2026
- Ohad HammerDirector, since March 2026
- Tim Jasper KnotnerusChief Executive Officer, Director, since March 2026
- Colin Michael BondDirector, since March 2026
- Angelika Martha JahreisDirector, since March 2026
- Philippe Constantin WieselChief Medical Officer, since March 2026
Recent Form 3, 4, and 5 filings for AGMB
- Director Epstein David R bought $103,500 worth of shares (15,000 units at $6.90), increasing direct ownership by 60% to 40,000 units (SEC Form 4)4 - AgomAb Therapeutics NV (0002020932) (Issuer)
- Director Epstein David R bought $88,800 worth of shares (10,000 units at $8.88) (SEC Form 4)4 - AgomAb Therapeutics NV (0002020932) (Issuer)
- Director Epstein David R bought $44,500 worth of shares (5,000 units at $8.90) (SEC Form 4)4 - AgomAb Therapeutics NV (0002020932) (Issuer)
- Director Epstein David R bought $86,350 worth of shares (10,000 units at $8.64) (SEC Form 4)4 - AgomAb Therapeutics NV (0002020932) (Issuer)
- Chief Financial Officer Kemula Pierre Thadee Victor bought $85,940 worth of shares (10,000 units at $8.59) (SEC Form 4)4 - AgomAb Therapeutics NV (0002020932) (Issuer)
- Chief Executive Officer Knotnerus Tim Jasper bought $94,380 worth of shares (11,000 units at $8.58) (SEC Form 4)4 - AgomAb Therapeutics NV (0002020932) (Issuer)
- SEC Form 4 filed by Director Garcia Marino4 - AgomAb Therapeutics NV (0002020932) (Issuer)
- SEC Form 4 filed by Director Patel Naimish4 - AgomAb Therapeutics NV (0002020932) (Issuer)
- SEC Form 3 filed by new insider Patel Naimish3 - AgomAb Therapeutics NV (0002020932) (Issuer)
- SEC Form 3 filed by new insider Garcia Marino3 - AgomAb Therapeutics NV (0002020932) (Issuer)
- SEC Form 3 filed by new insider Bond Colin Michael3 - Agomab Therapeutics NV (0002020932) (Issuer)
- SEC Form 3 filed by new insider Van Der Horst Paul Henryk3 - Agomab Therapeutics NV (0002020932) (Issuer)
- SEC Form 3 filed by new insider Knotnerus Tim Jasper3 - Agomab Therapeutics NV (0002020932) (Issuer)
- SEC Form 3 filed by new insider Borderias Andrea Saez3 - Agomab Therapeutics NV (0002020932) (Issuer)
- SEC Form 3 filed by new insider Verduyn-Van Weegen Felice Isabel3 - Agomab Therapeutics NV (0002020932) (Issuer)
- SEC Form 3 filed by new insider Epstein David R3 - Agomab Therapeutics NV (0002020932) (Issuer)
- SEC Form 3 filed by new insider Lefever Ellen3 - Agomab Therapeutics NV (0002020932) (Issuer)
- SEC Form 3 filed by new insider Hammer Ohad3 - Agomab Therapeutics NV (0002020932) (Issuer)
- SEC Form 3 filed by new insider Kemula Pierre Thadee Victor3 - Agomab Therapeutics NV (0002020932) (Issuer)
- SEC Form 3 filed by new insider Wiesel Philippe Constantin3 - Agomab Therapeutics NV (0002020932) (Issuer)
- SEC Form 3 filed by new insider Jahreis Angelika Martha3 - Agomab Therapeutics NV (0002020932) (Issuer)